<DOC>
	<DOC>NCT02260193</DOC>
	<brief_summary>The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in subjects with end stage renal disease undergoing chronic hemodialysis.</brief_summary>
	<brief_title>16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Subjects With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Key 18 to 79 years inclusive Chronic Kidney Disease (CKD) Stage 5 on chronic hemodialysis for at least 3 months Anemia secondary to CKD treated with erythropoiesis stimulating agent and intravenous iron Key BMI &gt;44.0 kg/m2 Transfusion within 8 weeks prior to Screening ALT or total bilirubin &gt;1.25x ULN Uncontrolled hypertension Class III or IV congestive heart failure Myocardial infarction, acute coronary syndrome, stroke or transient ischemic attack within 6 months prior to Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>anemia</keyword>
	<keyword>end stage renal disease</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>dialysis</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>kidney</keyword>
	<keyword>oral anemia treatment</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>hypoxia-inducible factor propyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>